Regenerative Skincare: EGF, Exosomes, PDRN & Peptides

“Regenerative” is currently doing the work of seven different nouns.

Growth factors, epidermal growth factor, fibroblast-conditioned media, exosomes, PDRN, polynucleotides, peptides, PRP, and post-procedure serums are routinely arranged under one glossy umbrella. The promise is that these products do something more intelligent than moisturize: signal, repair, remodel, communicate, or persuade tissue to behave younger.

METHOD · CLAIMSWhat a claim has to climb.

01WordingWhat is stated, what is implied, what is unsaid?
02MechanismIs there a plausible route from ingredient to result?
03EvidenceWho ran the study, who paid, how many people?
04RelevanceWas it tested on skin, at this dose, for this long?
05VerdictWorth it, conditional, or not yet — and for whom.

A claim that skips a rung has not earned the one above it.

What a claim has to climb. Five rungs between a sentence on a box and a verdict. Each one is a question the claim has to survive before the next is worth asking.

Some of that language comes from legitimate biology. The problem is that biologically active-sounding materials do not share one evidence file, and the umbrella is the thing preventing you from noticing.

So here they are, unstacked.

Seven materials sold under one word, and what each one actually is
Sold as	What the material is	Where it comes from	What its evidence is made of	U.S. regulatory position
Growth factors	A function category, not an ingredient. Signaling proteins involved in cell proliferation, migration, differentiation, angiogenesis and wound repair. FGF, TGF-beta, PDGF and VEGF have different targets and roles	Recombinant protein, or a blend the label often does not itemize	A 2023 systematic review: 33 studies, 1,180 participants, nine randomized controlled trials. Investigator-assessed improvements generally modest; the literature highly heterogeneous	Cosmetic, until the claim moves it
EGF	One growth factor, with a specific receptor and pathway. Not a synonym for the category	Recombinant protein	Marketed for photoaging and post-procedure recovery. A large protein on intact skin still has a delivery problem that “contains EGF” does not answer	Cosmetic
Conditioned media	A complex signaling mixture — secretions, lysates, multiple cytokines and growth factors — rather than one purified protein	Cultured cells	Hard to compare at all: two products described the same way can have entirely different biological contents	Cosmetic
Peptides	Smaller signal, carrier, enzyme-inhibiting or neurotransmitter-inhibiting molecules. Not growth factors, whatever the “cell-signaling” copy implies	Synthesized sequences	Sequence- and formula-specific. Does not transfer from one peptide product to another	Cosmetic
PDRN / polynucleotides	DNA-derived fragments. A nucleotide material, not a protein	Salmon-derived nucleotides and similar sources	A regenerative-medicine literature tied to wound repair and tissue signaling, mostly from injectable and other medical contexts. Topical delivery is only beginning to be examined directly	The route is part of the evidence, and the route usually changes on the way to the bottle
Exosomes	Extracellular vesicles carrying proteins, lipids, nucleic acids and other cargo. Delivery packages, not growth factors in a bottle	Cultured cells	Genuinely interesting biology. Not a standardized finished-product evidence base	FDA has stated that there are no FDA-approved exosome products
PRP / PRF	Autologous blood-derived preparations containing platelet-associated growth factors	Your own blood	Results depend on preparation method, platelet concentration, leukocyte content, activation, delivery, indication and combination procedure	A procedure, not a bottle. PRP data cannot validate a topical serum because both involve signaling proteins

Read down the last column rather than the first. The word on the front of the box is the only thing these seven rows have in common.

The clinical literature is promising and still modest

A 2023 systematic review of topical growth-factor preparations for facial rejuvenation identified 33 studies and 1,180 participants, including nine randomized controlled trials. Investigator-assessed improvements were generally modest, and the literature was highly heterogeneous across sources, combinations, formulations, and endpoints. Several comparative randomized trials did not show statistically significant differences between treatments.

That is a more useful conclusion than either “growth factors are proven” or “they are useless.” There is evidence. It is not yet a category where one product’s result tells you anything about the next one, which is precisely the inference the shelf is arranged to encourage.

Note also what “modest” has to mean next to the money. Two products described as “growth factor serum” may contain entirely different biological material at entirely different prices, and neither one is obliged to tell you which.

Barrier disruption changes everything

A cosmetic applied to intact skin faces the stratum corneum. A product applied immediately after ablative laser or microneedling may encounter a temporarily altered barrier. That can improve delivery and simultaneously raise the stakes on sterility, composition, intended route and preservative systems.

The procedure does not confer approval on whatever vial is placed next to it. That is the single most expensive assumption in this category, and it is made in a treatment room with your face already numb.

“Stem cell” language usually needs translation too

Some skincare uses “stem cell conditioned media,” “stem cell proteins,” or plant stem-cell language. These phrases can describe very different materials. A cosmetic containing botanical stem-cell extract is not a stem-cell therapy. A human-cell-conditioned medium is not a live stem-cell treatment.

The source, processing, actual contents, and claims should be named plainly enough that you are not reverse-engineering the biology from branding while standing at a counter.

The regulator has already drawn the line the marketing keeps stepping over

FDA determines whether a topical product is a cosmetic or a drug partly by intended use. Claims to regenerate cells, affect body structure or function, treat disease, or produce wound healing can move a product outside ordinary cosmetic territory.

Which puts this category in an interesting position, because its favorite verbs — regenerate, repair tissue, stimulate growth, remodel — are being used as literal biological claims and then defended as poetry when anyone asks.

A high-tech bottle can still be a moisturizer with a research problem

Many growth-factor and regenerative formulas also contain glycerin, the usual humectants, silicones, emollients, peptides, niacinamide, antioxidants, and barrier-support ingredients. Those can make the skin look and feel better regardless of the headline biological.

That is not a flaw. It does mean the improvement you see may not prove that the prestige ingredient was responsible — and the prestige ingredient is the entire reason for the price.

Buy the finished product’s evidence, or do not buy the story

Vanity: this category contains some of the most interesting formulation and translational science in aesthetics. Topical growth factors have a real, if heterogeneous, clinical literature. PDRN has an evolving route-specific evidence base. Peptides can be rational actives. PRP is a legitimate procedural category in selected uses.

Vice: the umbrella lets every technology borrow prestige from every other one. Exosomes borrow from stem-cell science. Serums borrow from wound healing. Peptides borrow from protein signaling. PDRN borrows from injectable regenerative medicine. Nothing in that circle of credit is a finished-product result.

So the rule is simple enough to apply in a shop. If the evidence being offered was generated on the thing in the bottle, at the route it will be used, it counts. If it was generated on a raw material, a cell culture, an injectable version, or a different source entirely, it is background reading someone has priced at two hundred dollars. For the in-clinic version of this problem — injectables, boosters and what any of them are legally approved for — that conversation happens at the consultation, not the counter.

Sources worth opening

Method note: This is a category translator, not a recommendation for biologic or regenerative procedures. It follows my editorial standards.